T1	Participants 636 687	340 patients were Ph/BCR-ABL positive and evaluable
T2	Participants 949 1028	534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU)
T3	Participants 1653 1733	105 (20%) underwent allogeneic stem cell transplantation in first chronic phase.
